NCT03493685 | Phase 3 | Interventional
Have you or a loved one been diagnosed with focal segmental glomerulosclerosis? You may be eligible to participate in a focal segmental glomerulosclerosis clinical trial.
- Currently Recruiting
- Male & Female Participants
- 8-75 years old
*This study is looking to recruit 300 participants
To determine the long-term nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with primary focal segmental glomerulosclerosis (FSGS).
To get started, select a research facility. All study-related procedures will take place at the facility you select.
Royal Adelaide Hospital Recruiting – Port Road, Adelaide, South Australia, AUS 5000
Washington Nephrology Associates Recruiting – 4141 Duke Street, Alexandria, VA, USA 22304